{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:23:13Z","timestamp":1776349393131,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Open Project of Hubei Key Laboratory","award":["2023KFZZ010"],"award-info":[{"award-number":["2023KFZZ010"]}]},{"name":"the Natural Science Foundation of Hubei Province","award":["2024AFB111"],"award-info":[{"award-number":["2024AFB111"]}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["82371079"],"award-info":[{"award-number":["82371079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2023YFC2308404"],"award-info":[{"award-number":["2023YFC2308404"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The C\u2011reactive protein\u2013triglyceride glucose index (CTI), a composite marker of systemic inflammation and metabolic status, has been associated with cardiovascular and cerebrovascular risk. Its role in central retinal artery occlusion (CRAO) and subsequent adverse outcomes is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cohort study, 122 CRAO patients and 488 matched controls who underwent coronary angiography without coronary artery disease were analyzed. CTI was calculated as 0.412\u2009\u00d7\u2009ln [CRP (mg\/L)\u2009+\u20090.5\u2009\u00d7\u2009ln [TG\u2009\u00d7\u2009FPG(mg\/dL)]. Logistic regression adjusted for demographic, clinical, laboratory, and medication variables was used to explore the relationship between CTI and the risk of CRAO. Restricted cubic spline models assessed the dose\u2013response relationship between CTI and CRAO risk. The primary endpoint was CRAO and the secondary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs) during the 36\u2011month follow\u2011up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Higher CTI was independently associated with CRAO (adjusted OR\u2009=\u20091.46, 95% CI 1.14\u20131.88;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003). Restricted cubic spline analysis identified a CTI threshold of 9.810. CRAO patients with CTI\u2009&gt;\u20099.810 had a higher incidence of MACCEs (31.1% vs.\u202f10.1%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), particularly acute coronary syndromes (20.3% vs.\u202f7.1%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In subgroup analysis, CRAO patients with CTI\u2009&gt;\u20099.810 had the highest MACCEs rate (40.0%) and significantly greater risk of all\u2011cause death, stroke, and acute coronary syndromes (all adjusted\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) compared with other groups. Time\u2011to\u2011event analysis revealed that among all groups, CRAO patients with CTI\u2009&gt;\u20099.810 had the shortest median time to MACCEs occurrence at 6\u00a0months (IQR, \u202f4\u201311).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated CTI is independently associated with increased CRAO risk and predicts higher adverse MACCEs outcomes, suggesting CTI as a potential biomarker for risk stratification and secondary prevention in CRAO patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-025-03807-6","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T13:05:15Z","timestamp":1768223115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CRP\u2013TyG index and risk of new\u2011onset central retinal artery occlusion and subsequent major adverse cardiovascular and cerebrovascular events: a propensity score\u2011matched cohort study"],"prefix":"10.1186","volume":"31","author":[{"given":"Hang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"3807_CR1","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/s41433-024-03029-w","volume":"38","author":"C Chen","year":"2024","unstructured":"Chen C, Singh G, Madike R, Cugati S. Central retinal artery occlusion: a stroke of the eye. Eye Lond. 2024;38:2319\u201326.","journal-title":"Eye Lond"},{"key":"3807_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ajo.2025.03.040","volume":"276","author":"S Akosman","year":"2025","unstructured":"Akosman S, Yuan SM, Leigh A, et al. National trends in central retinal artery occlusion presentations and stroke workup in United States emergency department. Am J Ophthalmol. 2025;276:40\u20139.","journal-title":"Am J Ophthalmol"},{"key":"3807_CR3","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000366","volume":"52","author":"B Mac Grory","year":"2021","unstructured":"Mac Grory B, Schrag M, Biousse V, et al. Management of central retinal artery occlusion: a scientific statement from the American Heart Association. Stroke. 2021;52:e282\u201394.","journal-title":"Stroke"},{"key":"3807_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","volume":"396","author":"IU Scott","year":"2020","unstructured":"Scott IU, Campochiaro PA, Newman NJ, Biousse V. Retinal vascular occlusions. Lancet. 2020;396:1927\u201340.","journal-title":"Lancet"},{"key":"3807_CR5","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2023.4716","volume":"141","author":"KM Wai","year":"2023","unstructured":"Wai KM, Knapp A, Ludwig CA, et al. Risk of stroke, myocardial infarction, and death after retinal artery occlusion. JAMA Ophthalmol. 2023;141:1110\u20136.","journal-title":"JAMA Ophthalmol"},{"key":"3807_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.3068","volume":"6","author":"DD-J Hwang","year":"2023","unstructured":"Hwang DD-J, Lee K-E, Kim Y, et al. Incidence of retinal artery occlusion and related mortality in Korea, 2005 to 2018. JAMA Netw Open. 2023;6:e233068.","journal-title":"JAMA Netw Open"},{"key":"3807_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42247-2","volume":"13","author":"T Chen","year":"2023","unstructured":"Chen T, Wang Y, Li X, et al. Sex differences in major adverse cardiovascular and cerebrovascular event risk among central retinal artery occlusion patients. Sci Rep. 2023;13:14930.","journal-title":"Sci Rep"},{"key":"3807_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/09273948.2023.2173245","volume":"32","author":"T Chen","year":"2024","unstructured":"Chen T, Li Y, Wang Y, Li X, Wan Y, Xiao X. ApoB, non-HDL-C, and LDL-C are more prominent in retinal artery occlusion compared to retinal vein occlusion. Ocul Immunol Inflamm. 2024;32:534\u201340.","journal-title":"Ocul Immunol Inflamm"},{"key":"3807_CR9","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.1007\/s12035-024-04093-9","volume":"61","author":"C Wang","year":"2024","unstructured":"Wang C, Li Y, Feng J, et al. Plasmalogens and octanoylcarnitine serve as early warnings for central retinal artery occlusion. Mol Neurobiol. 2024;61:8026\u201337.","journal-title":"Mol Neurobiol"},{"key":"3807_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2023-325044","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang X, Liang A, et al. High-sensitivity C-reactive protein and risk of retinal artery occlusion and ischaemic stroke: a cross-cohort study. Br J Ophthalmol. 2025. https:\/\/doi.org\/10.1136\/bjo-2023-325044.","journal-title":"Br J Ophthalmol"},{"key":"3807_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s10792-024-03344-x","volume":"45","author":"HA Sirakaya","year":"2025","unstructured":"Sirakaya HA, Ayyildiz B, Sert II, Kucuk B, Koca S, Sirakaya E. The role of triglyceride-glucose index in central retinal artery occlusion. Int Ophthalmol. 2025;45:82.","journal-title":"Int Ophthalmol"},{"key":"3807_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02848-9","volume":"24","author":"H Ou","year":"2025","unstructured":"Ou H, Wei M, Li X, Xia X. C-reactive protein-triglyceride glucose index in evaluating cardiovascular disease and all-cause mortality incidence among individuals across stages 0-3 of cardiovascular-kidney-metabolic syndrome: a nationwide prospective cohort study. Cardiovasc Diabetol. 2025;24:296.","journal-title":"Cardiovasc Diabetol"},{"key":"3807_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02686-9","volume":"24","author":"G Huo","year":"2025","unstructured":"Huo G, Tang Y, Liu Z, Cao J, Yao Z, Zhou D. Association between C-reactive protein-triglyceride glucose index and stroke risk in different glycemic status: insights from the China Health and Retirement Longitudinal Study (CHARLS). Cardiovasc Diabetol. 2025;24:142.","journal-title":"Cardiovasc Diabetol"},{"key":"3807_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02876-5","volume":"24","author":"Y Chen","year":"2025","unstructured":"Chen Y, Jia W, Guo J, et al. Association between the C-reactive protein-triglyceride glucose index and new-onset coronary heart disease among metabolically heterogeneous individuals. Cardiovasc Diabetol. 2025;24:316.","journal-title":"Cardiovasc Diabetol"},{"key":"3807_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s42466-025-00413-z","volume":"7","author":"F Schlachetzki","year":"2025","unstructured":"Schlachetzki F, Feistenauer I, Ertl M, et al. Retinal ischemia due to different stages of atherosclerosis - insights from a retrospective study on central retinal artery occlusion. Neurol Res Pract. 2025;7:50.","journal-title":"Neurol Res Pract"},{"key":"3807_CR16","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1167\/iovs.16-19887","volume":"57","author":"KH Cho","year":"2016","unstructured":"Cho KH, Ahn SJ, Cho JH, et al. The characteristics of retinal emboli and its association with vascular reperfusion in retinal artery occlusion. Invest Ophthalmol Vis Sci. 2016;57:4589\u201398.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3807_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.semvascsurg.2015.04.002","volume":"27","author":"PA Stone","year":"2014","unstructured":"Stone PA, Kazil J. The relationships between serum C-reactive protein level and risk and progression of coronary and carotid atherosclerosis. Semin Vasc Surg. 2014;27:138\u201342.","journal-title":"Semin Vasc Surg"},{"key":"3807_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.038086","volume":"14","author":"Y Ling","year":"2025","unstructured":"Ling Y, Yuan S, Cheng H, et al. Exploring the link between C-Reactive Protein change and stroke risk: insights from a prospective cohort study and genetic evidence. J Am Heart Assoc. 2025;14:e038086.","journal-title":"J Am Heart Assoc"},{"key":"3807_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5:56.","journal-title":"Nat Rev Dis Primers"},{"key":"3807_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524\u201333.","journal-title":"Nature"},{"key":"3807_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.tcb.2020.09.006","volume":"30","author":"J Yan","year":"2020","unstructured":"Yan J, Horng T. Lipid metabolism in regulation of macrophage functions. Trends Cell Biol. 2020;30:979\u201389.","journal-title":"Trends Cell Biol"},{"key":"3807_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02835-0","volume":"24","author":"Y Sun","year":"2025","unstructured":"Sun Y, Guo Y, Ma S, et al. Association of C-reactive protein-triglyceride glucose index with the incidence and mortality of cardiovascular disease: a retrospective cohort study. Cardiovasc Diabetol. 2025;24:313.","journal-title":"Cardiovasc Diabetol"},{"key":"3807_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02869-4","volume":"24","author":"X Ma","year":"2025","unstructured":"Ma X, Ma X, Wang Y, Qiu G, Zhang C. Associations of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index with incident cardiovascular disease in middle-aged and older Chinese adults: a nationwide cohort study. Cardiovasc Diabetol. 2025;24:303.","journal-title":"Cardiovasc Diabetol"},{"key":"3807_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02244-9","volume":"23","author":"C Cui","year":"2024","unstructured":"Cui C, Liu L, Qi Y, et al. Joint association of TyG index and high-sensitivity C-reactive protein with cardiovascular disease: a national cohort study. Cardiovasc Diabetol. 2024;23:156.","journal-title":"Cardiovasc Diabetol"},{"key":"3807_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","volume":"118","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118:145\u201356.","journal-title":"Circ Res"},{"key":"3807_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","volume":"542","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177\u201385.","journal-title":"Nature"},{"key":"3807_CR27","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793\u2013801.","journal-title":"J Clin Invest"},{"key":"3807_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41577-021-00584-1","volume":"22","author":"P Roy","year":"2022","unstructured":"Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22:251\u201365.","journal-title":"Nat Rev Immunol"},{"key":"3807_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X, et al. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9:53.","journal-title":"Signal Transduct Target Ther"},{"key":"3807_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/CIRCRESAHA.108.192906","volume":"104","author":"K Tanigaki","year":"2009","unstructured":"Tanigaki K, Mineo C, Yuhanna IS, et al. C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res. 2009;104:1275\u201382.","journal-title":"Circ Res"},{"key":"3807_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2008.06.001","author":"R Muniyappa","year":"2008","unstructured":"Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am. 2008. https:\/\/doi.org\/10.1016\/j.ecl.2008.06.001.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3807_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20153775","author":"CA Meza","year":"2019","unstructured":"Meza CA, La Favor JD, Kim D-H, Hickner RC. Endothelial dysfunction: is there a hyperglycemia-induced imbalance of NOX and NOS? Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20153775.","journal-title":"Int J Mol Sci"},{"key":"3807_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.tcm.2010.02.002","volume":"19","author":"SU Eisenhardt","year":"2009","unstructured":"Eisenhardt SU, Habersberger J, Peter K. Monomeric C-reactive protein generation on activated platelets: the missing link between inflammation and atherothrombotic risk. Trends Cardiovasc Med. 2009;19:232\u20137.","journal-title":"Trends Cardiovasc Med"},{"key":"3807_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacc.2009.03.076","volume":"54","author":"C Antoniades","year":"2009","unstructured":"Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40\/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54:669\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"3807_CR35","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/eurheartj\/ehad304","volume":"44","author":"C Weber","year":"2023","unstructured":"Weber C, Habenicht AJR, von Hundelshausen P. Novel mechanisms and therapeutic targets in atherosclerosis: inflammation and beyond. Eur Heart J. 2023;44:2672\u201381.","journal-title":"Eur Heart J"},{"key":"3807_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62588-w","volume":"14","author":"R Shi","year":"2024","unstructured":"Shi R, Liu H, Xia K, et al. Circulating serum fibroblast growth factor 21 as risk and prognostic biomarker of retinal artery occlusion. Sci Rep. 2024;14:11854.","journal-title":"Sci Rep"},{"key":"3807_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ajo.2024.10.004","volume":"270","author":"S Hoyek","year":"2025","unstructured":"Hoyek S, Yuan M, Bejjani R, et al. Multimodal imaging characteristics and correlation to outcomes in patients with central retinal artery occlusion presenting to a large academic center. Am J Ophthalmol. 2025;270:35\u201351.","journal-title":"Am J Ophthalmol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03807-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:16:36Z","timestamp":1770642996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03807-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3807"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03807-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Renmin Hospital of  Wuhan University (Approval No.\u202f WDRY2022-K278). Written informed consent was obtained from all individual participants prior to their enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to partcipate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}